Advances in meningococcal vaccines

Clinical Practice

Volumn 9, Issue 1, 2012, Pages 101-117

  Pizza, Mariagrazia ^a   Detora, Lisa ^a   Wassil, James ^a  

^a 350 Massachusetts Avenue ^*

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; DIPHTHERIA TOXOID; DIPHTHERIA TOXOID CRM197; LIPOPOLYSACCHARIDE; LIPOPROTEIN; MENINGOCOCCUS VACCINE; MONOVALENT CATION; POLYSACCHARIDE VACCINE; PROTEIN FHBP; PROTEIN NADA; PROTEIN NHBA; RIFAMPICIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; CLINICAL FEATURE; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DRUG CONJUGATION; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; LISTERIA MONOCYTOGENES; MEDICAL DECISION MAKING; MENINGOCOCCOSIS; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING; VACCINE PRODUCTION; WILD TYPE;

EID: 84857583263     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/CPR.11.128     Document Type: Review

References (105)

1. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med. 263(16), 1511-1520 (2010).
2. Zollinger WD, Poolman, Maiden MC. Meningococcal serogroup B vaccines: will they live up to expectations? Exp. Rev. Vaccines 10(5), 559-561 (2011).
3. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders Co., PA, USA (2008).
4. Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl. 2), S54-S65 (2010).
5. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther. 11(7), 969-985 (2011).
6. Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Exp. Rev. Vaccines 10(5), 575-588 (2011).
7. Memish ZA, Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J. Infect. Public Health 3(4), 143-151 (2010).
8. Zuckerman JN, Bröker M, Worth C. 2010 FIFA world cup South Africa: travel health issues and new options for protection against meningococcal disease. Travel Med. Infect. Dis. 8(2), 68-73 (2010).
9. Stephens DS. Conquering the meningococcus. FEMS Microbiol. Rev. 31, 3-14 (2007). (Pubitemid 46058815)
10. Cooper B. DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y. Exp. Rev. Vaccines 10(1), 21-33 (2011).
11. Gardner P. Clinical practice. Prevention of meningococcal disease. N. Engl. J. Med. 355(14), 1466-1473 (2006). (Pubitemid 44511561)
12. Levy C, Taha MK, Weil Olivier C et al. Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr. Infect. Dis. J. 29(7), 618-623 (2010).
13. Brigham, Sandora TJ. Neisseria meningitidis: epidemiology, treatment, and prevention in adolescents. Curr. Opin. Pediatr. 21(4), 437-443 (2009).
14. Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J. Travel Med. 17(Suppl.), 3-8 (2010).
15. Memish ZA, Shibl AM. Consensus building and recommendations based on the available epidemiology of meningococcal disease in Gulf Cooperation Council States. Travel Med. Infect. Dis. 9(2), 60-66 (2011).
16. Bröker M, Cooper B, DeTora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C, W-135, and Y (Menveo®) in the context of treatment and prevention of invasive disease. Infect. Drug Resist. 4, 1-11 (2011).
17. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51-B63 (2009).
18. Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United states, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50(2), 184-191 (2010).
19. Śfadi MA, McIntosh D. Recognition and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev. Vaccines 10(12), 1717-1730 (2011).
20. De Gaudio M, Chiappini E, Galli L, De Martino M. Therapeutic management of bacterial meningitis in children: a systematic review and comparison of published guidelines from a European perspective. J. Chemotherapy 22(4), 226-237 (2010).
21. Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst. Rev. 18(4), CD004785 (2006).
22. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 54(RR-7), 1-21 (2005).
23. Katz LH, Zelazny A, Scharf S et al. Mass antibiotic treatment to stop an outbreak of meningococcal disease: a molecular analysis. Clin. Microbiol. Infect. 13(9), 943-946 (2007). (Pubitemid 47244147)
24. Rosenstein NE, Perkins BA, Stephens DS et al. Meningococcal disease. N. Engl. J. Med. 344(18), 1378-1388 (2001).
25. Thigpen MC, Whitney CG, Messonnier NE et al. Bacterial meningitis in the United States, 1998-2007. N. Engl. J. Med. 364(21), 2016-2025 (2008).
26. Furyk JS, Swann O, Molyneux E. Systematic review: neonatal meningitis in the developing world. Trop. Med. Int. Health 16(6), 672-679 (2011).
27. Gaschignard J, Levy C, Romain O, Cohen R, Bingen E, Aujard Y, Boileau P. Neonatal bacterial meningitis: 444 cases in 7 Years. Pediatr. Infect. Dis. J. 30(3), 212-217 (2011).
28. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines - an unfinished story. Lancet Infect. Dis. 10(2), 112-124 (2010).
29. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine 27(Suppl. 2), B30-B41 (2009).
30. Visintin C, Mugglestone MA, Fields EJ et al. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidelines. BMJ 340, C3209 (2010).
31. Sudarsanam T, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database Syst. Rev. 23(1), CD005437 (2008).
32. Maiden MC, Ibarz-Paven AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197, 737-743 (2008). (Pubitemid 351364476)
33. Bettinger JA, Scheifele DW, Le Saux N et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr. Infect. Dis. J. 28(3), 220-224 (2009).
34. Tyler KL. Chapter 28: a history of bacterial meningitis. Handb. Clin. Neuro. 95, 417-433 (2010).
35. de Souza AL, Seguro AC. Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease. J. Med. Microbiol. 57(Pt 11), 1313-1321 (2008).
36. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin. Infect. Dis. 50(Suppl. 2), S45-S53 (2010).
37. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum. Vaccin. 7(2), 170-182 (2011).
38. Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Exp. Rev. Vaccines 10(5), 617-634 (2011).
39. Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl. 2), B3-B12 (2009).
40. Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, overexpressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29(7), 1413-1420 (2011).
41. Toneatto D, Oster P, Deboer AC et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum. Vaccine 7(7), 781-791 (2011).
42. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin. Vaccine Immunol. 18(3), 483-486 (2011).
43. Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51(10), 1127-1137 (2010).
44. Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect. Dis. 29(11), e71-e79 (2010).
45. WHO. Meningococcal Vaccines: WHO Position Paper, November 2011. Wkly Epidemiol. Rec. 47(86), 521-540 (2011).
46. Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 29, 3363-3371 (2011).
47. Pollard AJ, Perrett KP, Beverley PC Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213-220 (2009).
48. Findlow H, Borrow R, Hardelid P et al. Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy infants. Clin. Vaccine Immunol. 18(3), 424-429 (2011).
49. Bröker M, Costantino P, Detora L, McIntosh ED, Rappuoli R. Biochemical and biological characteristics of cross-reacting material 197 (CRM(197)), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 39(4), 195-204 (2011).
50. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine 28(34), 5513-5523 (2010).
51. Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25, 312-319 (2006).
52. Deeks ED. Meningococcal and quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo), in adolescents and adults. BioDrugs. 24(5), 287-297 (2010).
53. Bröker M, Costantino P, DeTora L, McIntosh ED, Rappuoli R. Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein and other potential clinical applications. Biologicals 39(4), 195-204 (2011).
54. de Whalley PC, Snape MD, Kelly DF et al. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. Pediatr. Infect. Dis. J. 30(11), E203-E208 (2011).
55. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7?year follow-up in Quebec, Canada. Pediatr. Infect. Dis. J. 30(7), 566-569 (2011).
56. Campbell H, Andrews N, Borrow R, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17(5), 840-847 (2010).
57. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Exp. Rev. Vaccines 8(7), 851-861 (2009).
58. Sow SO, Okoko BJ, Diallo A et al. Immunogenicity and safety of a meningococcal A conjugate vaccines in Africans. N. Engl. J. Med. 364(24), 2293-2304 (2011).
59. LaForce FM, Okwo-Bele J-M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Affairs 30(7), 1049-1057 (2011).
60. Choudhuri D, Huda T, Theodoratou E et al. An evaluation of emerging vaccines for childhood meningococcal disease. BMC Public Health 11(Suppl. 3), S29 (2011).
61. Colombini A, Badolo O, Gessner BD et al. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine 29(33), 5474-5480 (2011).
62. Macneil JR, Cohn AC, Zell ER et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. 30(6), 451-455 (2011).
63. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 60(3), 72-76 (2011).
64. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum. Vaccines. 7(2), 170-182 (2011).
65. Pace D. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults. Future Microbiol. 5(11), 1629-1640 (2010).
66. Deeks ED. Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo), in adolescents and adults. BioDrugs. 24(5), 287-297 (2010).
67. Stamboulian D, Lopardo G, Lopez P et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM (197) conjugate vaccine, MenACWYCRM, compared with licensed vaccines in adults in Latin America. Int J. Infect. Dis. 14(10), E868-E875 (2010).
68. Arguedas A, Soley C, Loaiza C et al. Safety and immunogenicity of one dose of MenACWYCRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 28(18), 3171-3179 (2010).
69. Jackson LA, Baxter R, Reisinger K et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin. Infect. Dis. 49(1), E1-E10 (2009).
70. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135, and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum. Vaccin. 6(11), 881-887 (2010).
71. Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr. Infect. Dis. J. 30(3), E41-E48 (2011).
72. Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups a, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 8(28), 744-753 (2010).
73. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27(1), 161-168 (2009).
74. Hodgson A, Forgor AA, Chandramohan D et al. A Phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in northern Ghana. PLoS ONE 3(5), e2159 (2008).
75. Omenaca F, Aristegui J, Tejedor JC et al. Combined Haemophilus influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines. Pediatr. Infect. Dis. J. 30(11), e216-e224 (2011).
76. Miller E, Andrews N, Waight P et al. Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. Clin. Vaccine Immunol. 201118(3), 367-372 (2011).
77. Bryant KA, Marshall GS, Marchant CD et al. Immunogenicity and safety of H. influenzae type b-N. meningitidis C/Y conjugate vaccine in infants. Pediatrics 127(6), E1375-E1385 (2011).
78. Mallet E, Brachet E, Fernsten P et al. Immunogenicity and safety of CRM (197) conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants. Vaccine 29(34), 5812-5819 (2011).
79. Sigurdardottir ST, Davidsdottir, K, Arason VA et al. Safety and immunogenicity of CRM197- conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine 26(33), 4178-4186 (2011).
80. Hung MC, Salim O, Williams JN, Heckels JE, Christodoulides M. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate. Infect. Immun. 79(9), 3784-3791 (2011).
81. Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine 27(Suppl. 2), B42-B50 (2009).
82. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccin. 3(6), 390-394 (2007).
83. Serruto D, Rappuoli R. Post-genomic vaccine development. FEBS Lett. 580(12), 2985-2992 (2006). (Pubitemid 43729171)
84. Mora M, Donati C, Medini D, Covacci A, Rappuoli R. Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr. Opin. Microbiol. 9(5), 532-536 (2006). (Pubitemid 44397631)
85. Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J. Clin. Invest. 119(9), 2515-2525 (2009).
86. Pajon R, Yero D, Niebla O et al. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. Vaccine 11, 28(2), 532-541 (2009).
87. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA. 103, 10834-10839 (2006). (Pubitemid 44148381)
88. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27(21), 2794-2803 (2009).
89. Budroni S, Siena E, Hotopp C et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc. Natl Acad. Sci. USA 108(11), 4494-4499 (2011).
90. Mendum TA, Newcombe J, McNeilly CL, McFadden J. Towards the immunoproteome of Neisseria meningitidis. PLoS ONE 4(6), e5940 (2009).
91. Piet JR, Huis in 't Veld RA, van Schaik BD et al. Genome sequence of Neisseria meningitidis serogroup B strain H44/76. J. Bacteriol. 193(9), 2371-2372 (2011).
92. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev. 31(1), 89-96 (2007). (Pubitemid 46058824)
93. Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA 107(45), 19490-19495 (2010).
94. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl. 2), B112-B116 (2009).
95. Findlow J, Lowe A, Deane S et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine 23(20), 2623-2627 (2005). (Pubitemid 40380807)
96. Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine 24(10), 1569-1577 (2006). (Pubitemid 43238232)
97. Mascioni A, Bentley BE, Camarda R et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem. 284(13), 8738-8746 (2009).
98. McNeil LK, Murphy E, Zhao XJ. et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27(25-26), 3417-3421 (2009).
99. Ala'aldeen DA, Flint M, Oldfield NJ et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 28(48), 7667-7675 (2010).
100. Jiang HQ, Hoiseth SK, Harris SL et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28(37), 6086-6093 (2010).
101. Harris SL, Zhu D, Murphy E et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum. Vaccin. 7(Suppl.), 68-74 (2011).
102. Oster P, Keyserling H, Ympa E et al. First use in adolescents of an investigational recombinant meningococcal B vaccine developed by reverse vaccinology. Presented at: Meningitis and Septicaemia in Children and Adults 2009 - Meningitis Research Foundation. London, UK, 11-12 November 2009.
103. Brunelli B, Del Tordello E, Palumbo E et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 29(5), 1072-1081 (2011).
104. Donnelly JJ, Giuliani MM, Comanducci M. Defining a Neisseria meningitidis group B (MenB) strain pool for estimating vaccine effectiveness. Presented at: 17th International Pathogenic Neisseria Conference. Banff, Alberta, Canada, 11-16 September 2010.
105. Suburban Emergency Management Project.www.semp.us/publications/biot- reader. php?biotid=389